| Literature DB >> 33203157 |
Elena Salobrar-Garcia1,2,3, Carmen Méndez-Hernández3,4,5, Rosa de Hoz1,2,3, Ana I Ramírez1,2,3, Inés López-Cuenca1, José A Fernández-Albarral1, Pilar Rojas1,6, Surina Wang4, Julián García-Feijoo1,3,4,5, Pedro Gil7, Juan J Salazar1,2,3, José M Ramírez1,3,5.
Abstract
In Alzheimer's disease (AD), vascular changes could be caused by amyloid beta (Aβ) aggregates replacing the contractile smooth musculature of the arteriole walls. These changes happen in the brain vascular network, but also in the eye, and are related to decreased vascular density and low blood flow. In patients with Alzheimer's disease, thinning of the choroid and the retina has been shown. The aim of this prospective study was to assess the retinal and choroidal vascular systems, analyzing the choroidal thickness with optical coherence tomography (OCT), the foveal avascular zone (FAZ) with OCT-angiography (OCTA), and the optic nerve head (ONH) hemoglobin with the Laguna ONhE program, to evaluate which of the two ocular vascular systems shows earlier changes in mild AD patients. These patients, compared to controls, showed a significantly thinner choroid at all the analyzed points, with the exception of the temporal macula (at 1000 and 1500 µm from the fovea). On the other hand, the FAZ and ONH hemoglobin did not show significant differences. In conclusion, a thinner choroid was the main ocular vascular change observed in mild AD patients, while the retinal vessels were not yet affected. Therefore, choroidal thickness could be used an early biomarker in AD.Entities:
Keywords: Alzheimer’s; Laguna ONhE; OCT; OCTA; choroid; eye vascular network; optic nerve head hemoglobin; retina
Year: 2020 PMID: 33203157 PMCID: PMC7712569 DOI: 10.3390/jpm10040231
Source DB: PubMed Journal: J Pers Med ISSN: 2075-4426
Clinical evaluation of AD patients and ophthalmological inclusion criteria.
| Clinical Evaluation of AD Patients | ||
|---|---|---|
| Geriatrician Evaluation | Ophthalmological Evaluation | |
| Tests | Inclusion criteria | |
| Review of medical reports | Refraction | < ± 5 spherocylindrical |
| Caregiver interview | Biomicroscopy | AREDS < 2 |
| Physical and neurological examinations | Visual acuity | >0.5 dec |
| Psychometric test MMSE | Intraocular pressure | <21 mmHg |
| Neuroimaging techniques | Color fundus photography | Free of ocular disease |
| Routine laboratory testing for dementia | OCT/OCTA | Good quality scans with no artefacts |
(AD: Alzheimer’s Disease; AREDS: Age-Related Eye Disease group; MMSE: Mini Mental State Examination; dec: decimal scale; OCT: optical coherence tomography; OCTA: OCT angiography).
Figure 1Measurement of the choroidal thickness and Foveal Avascular Zone (FAZ). (A) Spectralis OCT analysis of choroidal thickness: (A1) retinal zone analyzed; (A2) choroidal thickness quantification (μm). (B) OCTA analysis of the FAZ; yellow circle delimiting the avascular area of each plexus: (B1) superficial capillary plexus; (B2) deep capillary plexus.
Median choroidal thickness and p-value in mild AD patients and the control group.
| Control | Mild AD | ||
|---|---|---|---|
| ( | ( | ||
| MMSE | 30.0 (28.75–30.0) | 26.0 (21.5–29.0) | |
| Subfovea | 257.0 (216.0–275.0) | 201.5 (175.0–233.7) | |
| Temp 500 µm | 253.0 (218.0–281.0) | 197.5 (173.7–249.5) | |
| Temp 1000 µm | 232.0 (207.0–278.0) | 213.5 (182.2–240.2) | 0.150 |
| Temp 1500 µm | 237.0 (189.0–272.0) | 218.5 (186.2–249.2) | 0.434 |
| Nas 500 µm | 232.0 (204.0–272.0) | 195.0 (159.5–233.7) | |
| Nas 1000 µm | 221.0 (198.0–261.0) | 200.0 (169.2–216.2) | |
| Nas 1500 µm | 213.0 (182.0–252.0) | 186.0 (168.5–202.5) | |
| Sup 500 µm | 248.0 (207.0–261.0) | 208.5 (166.2–236.5) | |
| Sup 1000 µm | 244.0 (202.0–273.0) | 208.5 (165.5–241.0) | |
| Sup 1500 µm | 237.5 (209.0–282.0) | 219.0 (166.5–230.0) | |
| Inf 500 µm | 241.5 (207.7–276.2) | 199.5 (164.2–234.0) | |
| Inf 1000 µm | 245.0 (214.2–288.0) | 207.0 (169.7–236.2) | |
| Inf 1500 µm | 251.5 (214.7–269.7) | 213.5 (166.0–240.0) |
Median (interquartile range); * p < 0.05 (in bold), Mann–Whitney U test. (AD: Alzheimer’s disease; MMSE: Mini Mental State Examination; vs: versus; Temp: temporal; Nas: nasal; Sup: superior; Inf: inferior).
Median Foveal Avascular Zone and p-value in mild AD patients and the control group.
| Control | Mild AD | ||
|---|---|---|---|
| ( | ( | ||
|
| 29.0 (28.5–30.0) | 26.5 (24.0–30.0) | |
|
| 0.54 (0.43–0.69) | 0.71 (0.51–0.80) | 0.288 |
|
| 0.28 (0.19–0.36) | 0.29 (0.22–0.46) | 0.357 |
Median (interquartile range); *p < 0.05 (in bold), Mann-Whitney U test (AD: Alzheimer’s Disease; FAZ: foveal avascular zone).
Percentage of hemoglobin in the optic nerve head (ONH) analyzed using photographs of the optic nerve with the Laguna ONhE program in the mild AD and control groups.
| Control | Mild AD | Mild AD vs. Control | |||
|---|---|---|---|---|---|
| ( | ( | % Mean Variation | |||
|
| 30 (30–30) | 23 (21–26.5) |
| ||
|
| 66.1 (62.55–70.65) | 64 (55.65–73.95) | 6.65 | 0.608 | |
|
| S1 | 72 (67.15–77) | 72.2 (56.8–79.85) | 1.46 | 0.792 |
| S2 | 71 (66.65–75.55) | 67.1 (56.6–76) | 1.59 | 0.259 | |
| S3 | 65.5 (60.95–71.5) | 60.7 (56.9–72.15) | 3.30 | 0.352 | |
| S4 | 70.9 (65.95–76.1) | 71.5 (58.95–79.75) | 2.70 | 0.849 | |
| S5 | 70.8 (65.4–74.4) | 69.3 (56.35–75.6) | 0.79 | 0.495 | |
| S6 | 67.1 (58.75–70.1) | 63.9 (55.65–69.15) | 2.61 | 0.253 | |
| S7 | 69 (63.75–73.55) | 68 (60.4–78.75) | −3.11 | 0.901 | |
| S8 | 70 (64.2–73.7) | 66.9 (58.7–77.8) | −1.36 | 0.764 | |
| S9 | 67 (58.8–70.9) | 62.6 (51.75–71.9) | 0.69 | 0.235 | |
| S10 | 66.1 (57.05–72.4) | 69.2 (58.15–81.5) | 3.21 | 0.229 | |
| S11 | 66.4 (61.4–70.25) | 67.3 (57.4–77) | −4.31 | 0.553 | |
| S12 | 63.6 (57.9–69.1) | 63.3 (53.7–72.15) | −1.84 | 0.775 | |
| S13 | 65 (56.45–71.1) | 69.3 (56.45–81) | 1.08 | 0.226 | |
| S14 | 66.3 (60.1–70.4) | 69.2 (55.4–75.05) | −4.45 | 0.468 | |
| S15 | 62.5 (58.05–68.2) | 60.2 (53.8–71.6) | −1.47 | 0.843 | |
| S16 | 66.5 (60.8–72.85) | 69.1 (57.5–79.7) | 0.86 | 0.66 | |
| S17 | 68.3 (64.15–73.85) | 66.9 (58.5–79.1) | −1.86 | 0.965 | |
| S18 | 64.8 (59.9–68.2) | 65.5 (56.15–72.55) | 0.56 | 0.665 | |
| S19 | 70.1 (65.3–76.35) | 69.9 (61.4–82.1) | 2.01 | 0.883 | |
| S20 | 71.1 (66.5–75.95) | 71.8 (60.1–77.8) | −0.33 | 0.538 | |
| S21 | 64.8 (59.05–71.7) | 61.9 (52.8–68.8) | 2.14 | 0.168 | |
| S22 | 71.4 (65.35–78.4) | 70 (57.75–83.75) | 4.12 | 0.764 | |
| S23 | 70.7 (67.1–76.15) | 68.3 (57.65–74.5) | 1.52 | 0.235 | |
| S24 | 65.7 (58.45–72.25) | 62.4 (53.3–69.05) | 3.66 | 0.177 | |
Median (interquartile range); * p < 0.05 (in bold), Mann—Whitney U test (AD: Alzheimer’s disease; vs.: versus; S: sector).
Figure 2Colorimetric percentage differences of hemoglobin in the optic nerve head, analyzed using photographs of the optic nerve with the Laguna ONhE program, between the mild AD and control groups. Blue tones: decreased hemoglobin in patients with AD compared to the control group. Red tones: increased hemoglobin in patients with AD compared to the control group. Abbreviations: Sup (superior), Inf (inferior), Temp (temporal), Nas (nasal), S (sector).